ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2025

Abstract Number: 2421

Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria

Nicholas Bauer1, Philip Carlucci2, Rufei Lu1, Carla Guthridge1, Tayte Stephens3, Benjamin Jones4, Wade DeJager5, Susan Macwana1, Andrea Fava6, Sanchit Sanyal7, Erin Carter8, Mala Masson9, Jennifer Anolik10, Jennifer Barnas11, Peter Izmirly12, H Michael Belmont13, Kelly Ruggles14, Study Team ALE06 Clinical1, Brad Rovin15, Jill Buyon16, Michelle Petri17, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2New York University School of Medicine, New York, NY, 3University of Oklahoma Health Science Center, Oklahoma City, OK, 4Oklahoma State University, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Johns Hopkins University, Baltimore, MD, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8New York University Grossman School of Medicine, New York, NY, 9NYU Langone Medical Center- Division of Rheumatology, New York, NY, 10University of Rochester Medical Center, Rochester, NY, 11University of Rochester, Rochester, NY, 12New York University Grossman School of Medicine, New York, NY, 13NYU School of Medicine, New York, NY, 14NYU Grossman School of Medicine, Brooklyn, NY, 15The Ohio State University, Columbus, OH, 16NYU Grossman School of Medicine, New York, NY, 17Johns Hopkins University School of Medicine, Timonium, MD

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, B-Lymphocyte, immunology, Lupus nephritis, Systemic lupus erythematosus (SLE)

Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Autoreactive B cell populations play a key role in the pathogenesis of lupus nephritis (LN). Therefore, it is hypothesized that dysregulation in the B cell compartment may be an early indicator of kidney involvement in SLE. The AMP-AIM lupus nephritis study was initiated to identify molecular drivers of kidney disease in SLE patients with minimal proteinuria (considered “early” disease). Accordingly, this study leveraged CyTOF performed at the time of a kidney biopsy in AMP-AIM to characterize alterations within the B cell lineage between LN and non-LN cases and within LN disease classes.

Methods: Twenty-five patients fulfilling diagnostic criteria for SLE with a urine protein creatinine ratio between 0.25 – 0.49 without a history of LN but an additional risk factor for LN including active sediment and/or serologies were enrolled in AMP-AIM. Whole blood was collected at the time of their kidney biopsy and stained at the point of collection on the same day using the Maxpar Direct Immune Profiling Assay (MDIPA), a comprehensive panel of 30 markers to capture the broad immune phenotype of the samples. The samples were stabilized and shipped to a central location where data were captured using the CyTOF XT platform. Low-quality events were excluded with FlowCut and cells were gated to include only the B cell lineage. Dimension reduction and clustering were performed using ClusterX. All pairwise comparisons were made with the Wilcoxon rank-sum test.

Results: Table 1 shows the clinical characteristics of the patients with and without LN at biopsy. ClusterX captured a total of 15 clusters within B cells (Figure 1A & 1B). Two clusters, both CD11c positive, were elevated in LN vs non-LN cases (Figure 2). One was IgD positive (B12) and the other was IgD negative (B6) (p=0.023 and p=0.0024 respectively). A naïve B cell cluster characterized as CXCR3 positive and CXCR5 positive (B9) was also expanded in LN compared to non-LN cases (p=0.0048). Surprisingly, elevated frequencies for all three clusters were seen in class V compared to class III (B6, p=0.18; B9, p=0.052; B12, p=0.082) (Figure 2). An additional CXCR5 and CCR7 positive naïve B cell cluster (B5) was also significantly elevated in class V compared to class III (p=0.034). These differences were also reflected in hierarchical clustering of the samples (Figure 2B).

Conclusion: Whole blood profiling at the point of collection, which likely reduced artifactual findings compared to prior studies which have relied on PBMCs, yielded several differences between LN and non-LN cases at the time of biopsy. These data suggest B cell dysregulation may be detected “early” in kidney involvement in SLE patients, especially with class V histology. Whole blood profiling at the point of collection, which likely reduced artifactual findings compared to prior studies which have relied on PBMCs, yielded several differences between LN and non-LN cases at the time of biopsy. These data suggest B cell dysregulation may be detected “early” in kidney involvement in SLE patients, especially with class V histology.

Supporting image 1Table 1: Clinical characteristics of patients with and without LN. Data are represented as median [IQR], or n (%). *4 non LN but unknown other histology, 2 arteriosclerosis, 1 diabetic nephropathy, 1 microangiopathy.

Supporting image 2Figure 1. B cell clusters in LN and Non LN cases. (A): Uniform Manifold Approximation and Projection (UMAP) dimension reduction visualizing the different B cell clusters (top left) and the differences in their density (top right) (B): Marker expression in each of the B cell clusters (C): PCA based on B cell clusters colored by biopsy histology.

Supporting image 3Figure 2. Four B cell clusters differentiate LN and non LN (A): Boxplots showing the four B cell clusters significantly different between Non LN and LN cases. LN is further divided into mesangial, membranous, and proliferative histology. P-values for Non LN vs LN and membranous vs proliferative are reported (B): Heatmap showing the expression of each cluster in all cases.


Disclosures: N. Bauer: None; P. Carlucci: None; R. Lu: None; C. Guthridge: None; T. Stephens: None; B. Jones: None; W. DeJager: None; S. Macwana: None; A. Fava: Artiva, 2, AstraZeneca, 1, 2, Bain Capital, 2, Biogen, 1, Bristol-Myers Squibb(BMS), 2, Exagen, 5, 9, Quotient Therapeutics, 2, UCB, 6, Zenas, 2; S. Sanyal: None; E. Carter: None; M. Masson: None; J. Anolik: None; J. Barnas: None; P. Izmirly: Hansoh Bio, 2; H. Belmont: None; K. Ruggles: None; S. ALE06 Clinical: None; B. Rovin: Alexion, 2, Artiva, 2, 11, AstraZeneca, 2, Aurinia, 2, 5, Biogen, 2, 5, Bristol Myers Squibb, 2, Cabelleta, 2, Century, 2, F. Hoffman-La Roche Ltd/Genentech, Inc., 2, GlaxoSmithKlein(GSK), 2, Novartis, 2; J. Buyon: Artiva Biotherapeutics, 2, Biogen, 2, Bristol-Myers Squibb(BMS), 2, Celgene, 2, CLIMB Bio Operating, 2, GlaxoSmithKlein(GSK), 2, Janssen, 2, Related Sciences, 2, UCB, 2; M. Petri: Amgen, 2, AnaptysBio, 2, Annexon Bio, 2, AstraZeneca, 2, 5, Atara Biosciences, 2, Aurinia, 2, 5, Autolus, 2, Bain Capital, 2, Baobab Therapeutics, 2, Biocryst, 2, Biogen, 2, Boxer Capital, 2, Cabaletto Bio, 2, Caribou Biosciences, 2, CTI Clinical Trial and Consulting Services, 2, CVS Health, 2, Dualitybio, 2, Eli Lilly, 2, 5, EMD Serono, 2, Emergent, 2, Escient Pharmaceuticals, 2, Exagen, 5, Exo Therapeutics, 2, Gentibio, 2, GlaxoSmithKlein(GSK), 2, 5, iCell Gene Therapeutics, 2, Innovaderm Research, 2, IQVIA, 2, Janssen, 5, Kezar Life Sciences, 2, Kira Pharmaceuticals, 2, Nexstone Immunology, 2, Nimbus Lakshmi, 2, Novartis, 2, Ono Pharma, 2, PPD Development, 2, Proviant, 2, Regeneron, 2, Seismic Therapeutic, 2, Senti Biosciences, 2, Sinomab Biosciences, 2, Steritas, 2, Takeda, 2, Tenet Medicines, 2, TG Therapeutics, 2, UCB, 2, Variant Bio, 2, Worldwide Clinical Trials, 2, Zydus, 2; J. James: GlaxoSmithKlein(GSK), 2, Progentec, 5; J. Guthridge: None.

To cite this abstract in AMA style:

Bauer N, Carlucci P, Lu R, Guthridge C, Stephens T, Jones B, DeJager W, Macwana S, Fava A, Sanyal S, Carter E, Masson M, Anolik J, Barnas J, Izmirly P, Belmont H, Ruggles K, ALE06 Clinical S, Rovin B, Buyon J, Petri M, James J, Guthridge J. Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/whole-blood-immune-phenotyping-reveals-cytometric-differences-in-b-cell-clusters-between-lupus-nephritis-and-non-lupus-nephritis-sle-patients-with-minimal-proteinuria/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-blood-immune-phenotyping-reveals-cytometric-differences-in-b-cell-clusters-between-lupus-nephritis-and-non-lupus-nephritis-sle-patients-with-minimal-proteinuria/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology